CORONA Remedies Ltd. (CORONA) Share Price Hits Fresh 52-Week High

CORONA Remedies Ltd. Share Price reaches a fresh 52-week high at Rs 2,135, marking a 1.39% increase. Market cap stands at Rs 12,653.72 crore.

CORONA Remedies Ltd. Share Price has reached a fresh 52-week high of Rs 2,135, reflecting a 1.39% increase from the previous close of Rs 2,105.8. The stock opened at Rs 2,119.75 and touched a high of Rs 2,147.6 during the trading session. With a market capitalisation of Rs 12,653.72 crore, CORONA Remedies Ltd. is attracting investor attention. The stock's performance is notable in the healthcare sector, where it competes with other significant players.

CORONA Remedies Ltd. Share Price Today: Price Action Analysis

Metric	Value
Current Price	Rs 2,135
Previous Close	Rs 2,105.8
Today's Change	+Rs 29.2 (+1.39%)
Day Open	Rs 2,119.75
Fresh 52-Week High	Rs 2,147.6
Day Low	Rs 2,097.05
Current Volume	1,025
Turnover	Rs 0.22 crore
Market Capitalisation	Rs 12,653.72 crore

CORONA Remedies Ltd. (CORONA) traded at Rs 2,135. versus the previous close of Rs 2,105.8, a rise of 1.39%. The stock opened at Rs 2,119.75, reached Rs 2,147.6, touched Rs 2,097.05. Reported volume was 1,025.

Today, CORONA Remedies Ltd. Share Price opened at Rs 2,119.75 and reached a high of Rs 2,147.6, setting a new 52-week high. The stock closed at Rs 2,135, up by Rs 29.2 or 1.39% from the previous close. The day's low was Rs 2,097.05, with a turnover of Rs 0.22 crore and a volume of 1,025 shares. This price action highlights the stock's upward momentum, drawing attention from market participants.

CORONA Remedies Ltd. (CORONA) Fundamental Analysis

Metric	Value
Market Capitalisation	Rs 12,653.72 crore
P/E Ratio	30.28x
P/B Ratio	0.44x
ROE	-2.89%
ROCE	-0.26%

CORONA Remedies Ltd. was valued at a P/E ratio of 30.28x, a P/B ratio of 0.44x. These multiples provide valuation context, but they should not be labelled expensive or inexpensive without a comparable peer or sector benchmark.

Profitability and capital efficiency were represented by ROE of -2.89% and ROCE of -0.26%. ROE relates profit to shareholder equity, while ROCE measures returns generated on the capital employed in the business.

Sector and Industry Context

Metric	Value
Sector	Healthcare
Benchmark Scope	same sector
Company P/E Ratio	30.28x
Benchmark Median P/E	21.7x
Benchmark Average P/E	68.16x
Benchmark P/E Range	0x to 3,385.56x
Company P/B Ratio	0.44x
Benchmark Median P/B	1.9x
Company ROE	-2.89%
Benchmark Median ROE	10.73%
Company ROCE	-0.26%
Benchmark Median ROCE	13.2%
Company Market Capitalisation	Rs 12,653.72 crore
Benchmark Median Market Cap	Rs 138.42 crore

CORONA Remedies Ltd. (CORONA) is classified under sector: Healthcare.

CORONA Remedies Ltd. (CORONA) has a P/E ratio of 30.28x, which is above the benchmark median of 21.7x, a difference of +39.54%. P/E is a valuation multiple and is not, by itself, a buy or sell signal.

CORONA Remedies Ltd. (CORONA) has a ROE of -2.89%, which is below the benchmark median of 10.73%, a difference of -126.93%. CORONA Remedies Ltd. (CORONA) has a ROCE of -0.26%, which is below the benchmark median of 13.2%, a difference of -101.97%.

Track stocks reaching yearly peaks through the Univest 52-week-high screener. The peer table below provides the company-level comparison.

Peer Comparison

Company	Symbol	Market Cap (Cr)	P/E	P/B	ROE (%)	ROCE (%)
Dishman Carbogen Amcis Ltd.	DCAL	2,856.59	30.28	0.44	-2.89	-0.26
Kwality Pharmaceuticals Ltd.	KPL	2,686.76	40.11	8.17	28.21	26.35
Dr Agarwals Eye Hospital Ltd.	DRAGARWQ	2,432.22	34.7	7.02	-2.6	16.92
Sai Parenteral's Ltd.	SAIPARENT	2,415.06	171.06	3.16	13.9	12.97
Beta Drugs Ltd.	BETA	2,338.9	59.68	9.44	18.65	22.17

CORONA Remedies Ltd. (CORONA) has a P/E ratio of 30.28x compared with the displayed peer median of 40.11x. This is a relative valuation comparison, not a buy or sell signal. Its ROE of -2.89% compares with a peer median of 13.9% across the companies shown in the table. ROCE stood at -0.26% versus the displayed peer median of 16.92%, providing a capital-efficiency comparison. CORONA Remedies Ltd. (CORONA) has a market capitalisation of Rs 12,653.72 crore. Among the 5 peers shown, 0 have a larger market capitalisation.

Why Investors Are Watching CORONA Remedies Ltd.

• Fresh 52-week high at Rs 2,135, indicating strong price momentum.
• Market cap of Rs 12,653.72 crore, positioning it as a significant player in the healthcare sector.
• Mixed fundamental metrics with a high P/E ratio and negative profitability.
• Competitive sector positioning with a large market cap compared to peers.

About CORONA Remedies Ltd.

CORONA Remedies Ltd. operates in the healthcare sector, focusing on pharmaceuticals and healthcare solutions. The company is involved in the development, manufacturing, and marketing of a wide range of pharmaceutical products. With a strong market presence, CORONA Remedies Ltd. aims to address various healthcare needs through its innovative product offerings. The company's strategic focus on quality and innovation positions it as a key player in the healthcare industry.

Track CORONA Remedies Ltd. Share Price on Univest

Use CORONA Remedies Ltd. (CORONA) live share-price page, Univest 52-week-high screener, Univest market blogs to review live stock data, yearly-high lists and related market analysis.

Investors can track CORONA Remedies Ltd. Share Price, technical indicators, fundamental ratios, shareholding pattern, 52-week levels, and market insights on Univest for comprehensive analysis and informed decision-making.

Frequently Asked Questions

What is the current share price of CORONA Remedies Ltd.?

Ans. The current share price of CORONA Remedies Ltd. is Rs 2,135, marking a 1.39% increase from the previous close. The stock has reached a fresh 52-week high. The stock moved 1.39% during the session.

What is CORONA Remedies Ltd.'s market capitalisation?

Ans. CORONA Remedies Ltd. has a market capitalisation of Rs 12,653.72 crore, positioning it as a significant player in the healthcare sector. The company operates in the Healthcare sector. Its P/E ratio is 30.28x.

How does CORONA Remedies Ltd.'s P/E ratio compare to the sector?

Ans. CORONA Remedies Ltd.'s P/E ratio of 30.28 is above the sector median of 21.7 but below the sector average of 68.16, indicating a moderate valuation. The company trades at a P/E ratio of 30.28x.

What are CORONA Remedies Ltd.'s profitability metrics?

Ans. CORONA Remedies Ltd. has a negative ROE of -2.89% and a negative ROCE of -0.26%, contrasting with the sector medians of 10.73% and 13.2%, respectively. ROE stands at -2.89%. ROCE stands at -0.26%.

Who are CORONA Remedies Ltd.'s peers?

Ans. CORONA Remedies Ltd.'s peers include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., and Dr Agarwals Eye Hospital Ltd., among others in the healthcare sector. Comparable listed companies include Dishman Carbogen Amcis Ltd., Kwality Pharmaceuticals Ltd., Dr Agarwals Eye Hospital Ltd.

What is the sector context for CORONA Remedies Ltd.?

Ans. CORONA Remedies Ltd. operates in the healthcare sector, which includes 198 companies. The sector's P/E median is 21.7, with an average of 68.16. The stock belongs to the Healthcare sector.

How does CORONA Remedies Ltd.'s market cap compare to peers?

Ans. CORONA Remedies Ltd.'s market cap of Rs 12,653.72 crore is significantly larger than its peers, indicating a strong market position within the sector. The company operates in the Healthcare sector.

What is the P/B ratio of CORONA Remedies Ltd.?

Ans. CORONA Remedies Ltd. has a P/B ratio of 0.44, suggesting potential undervaluation relative to its book value compared to the sector median of 1.9. The company trades at a P/E ratio of 30.28x.